RINVOQ® – BiotechReality – Information Intelligence System for Biopharma

NORTH CHICAGO, Ill - AbbVie (ABBV) has reached a significant advancement in the development of upadacitinib (RINVOQ), a JAK inhibitor for autoimmune hair loss diseases, by announcing encouraging topline results from the second pivotal Phase 3 study assessing this medication for the treatment of severe alopecia areata. Trial Achieves Primary Endpoints with Strong Efficacy Results In contrast to just 1.5% of placebo patients, 45.2% of patients treated with upadacitinib 15 mg and 55.0% treated with 30 mg achieved 80% or more scalp hair coverage after 24 weeks, demonstrating the UP-AA Study 1's exceptional efficacy (p<0.001). The Severity of Alopecia Tool (SALT) score < 20 was used to measure these results. Patients with severe alopecia areata who had a mean baseline SALT score of 84.0, or roughly 16% scalp hair covering, showed a clinically significant improvement. Important secondary goals were also accomplished by the study; compared to 0.7% of patients who received a placebo, 35.2% and 45.8% of patients in the 15 mg and 30 mg groups, respectively, achieved 90% or more scalp hair coverage (SALT ≤ 10). Improvements in eyelash and eyebrow regrowth, as well as full scalp hair coverage (SALT 0) for both upadacitinib dosages, were additional secondary objectives. Read More: AbbVie Enters Into the Obesity Drug Market With a License Agreement Consistent Safety Profile Observed No new safety signals were found, and the safety profile stayed mostly in line with previously authorized indications. Compared to 0.7% in the placebo group, 1.9% and 1.8% of the 15 mg and 30 mg groups experienced treatment-emergent severe side events. Adverse event-related discontinuations were rare, impacting 1.1% and 1.5% of patients in the upadacitinib groups, respectively, whereas the placebo arm experienced no discontinuations. Acne, nasopharyngitis, elevated blood creatine phosphokinase, and upper respiratory tract infections were the most frequently reported adverse effects. There was only one instance of serious infection in the 30 mg and placebo groups, and none in the 15 mg group. Interestingly, no venous thromboembolic events, severe cardiovascular events, or deaths were adjudicated during the research. Read More: AbbVie’s RINVOQ® (upadacitinib) Receives U.S. FDA Approval for Giant Cell Arteritis Comprehensive Trial Design and Next Steps One of the most thorough assessments of alopecia areata treatment to date is the UP-AA clinical program. Two replication pivotal studies with independent randomization, investigation locations, data collection, and analysis are part of the M23-716 protocol. In 248 locations across the globe, 1,399 individuals with severe alopecia areata, ages 12 to 64, were randomly assigned to the trials. Participants who complete the initial studies are eligible for an extended trial that lasts up to 108 weeks. The study design involves various treatment sessions that span 52 weeks. Researchers can assess the long-term safety and maintenance of hair regeneration as well as the short-term effectiveness thanks to this thorough technique. Read More: AbbVie’s Atogepant (QULIPTA® / AQUIPTA®) Achieves Superiority Across All Endpoints in Phase 3 Migraine Study Regulatory Pathway and Future Availability These findings from Study 1 provide strong support for regulatory filings since they align with previously reported topline results from Study 2 of the Phase 3 UP-AA clinical program. For AbbVie, "submitting these data to regulatory bodies, bringing us one step closer to delivering upadacitinib to those living with this complex immune-mediated disease" is something that Dr. Wallace expressed excitement about. Regulatory bodies have not yet assessed the safety and effectiveness of upadacitinib for alopecia areata, and its use in this condition is currently unapproved. Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, Crohn's disease, atopic dermatitis, and giant cell arteritis are among the autoimmune diseases for which the medication is currently licensed. About RINVOQ and JAK Inhibition Scientists at AbbVie discovered and created the JAK inhibitor RINVOQ (upadacitinib). The medication showed preferential suppression of cytokine-induced STAT phosphorylation mediated by JAK1 and JAK1/JAK3 as opposed to JAK2/JAK2 mediated pathways in human leukocyte cellular tests. Upadacitinib is being investigated in Phase 3 clinical studies for conditions other than alopecia areata, including vitiligo, systemic lupus erythematosus, hidradenitis suppurativa, and Takayasu arteritis. Both Phase 3 studies' encouraging findings could be a breakthrough for people with severe alopecia areata, a disorder that can have a major negative influence on psychological health and quality of life. Upadacitinib may soon provide a new treatment option for this difficult autoimmune illness, since regulatory applications are planned. Information: AbbVie Last Modified:

Tag: RINVOQ®

AbbVie Reports Breakthrough Results for RINVOQ® (Upadacitinib) in Alopecia Areata Treatment

Areas Covered

Discover More

GSK Secures Japan Orphan Drug Designation for Risvutatug Rezetecan in Small-Cell Lung Cancer

Pfizer’s Talzenna + Xtandi Delivers Proven rPFS Breakthrough in HRR-Mutated mCSPC

Eli Lilly Declares Powerful 2% A1C Reduction and 17% Weight Loss in Landmark Phase 3 Trial Results of Retatrutide

ICOTYDE FDA Approval: J&J’s First-Line Oral Peptide Breakthrough for Plaque Psoriasis Treatment

Atirmociclib Phase 2 Breakthrough: Pfizer Declares Powerful Results for Metastatic Breast Cancer Treatment

EBGLYSS (lebrikizumab-lbkz) Delivers Remarkable Phase 3 Results for Pediatric Atopic Dermatitis Treatment